TG Therapeutics Completes Phase 3 ENHANCE Trial Enrollment for Simplified BRIUMVI Dosing in Multiple Sclerosis
Reuters
Oct 28, 2025
TG <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Completes Phase 3 ENHANCE Trial Enrollment for Simplified BRIUMVI Dosing in Multiple Sclerosis
TG Therapeutics Inc. has announced the completion of enrollment in the randomized cohort of its Phase 3 ENHANCE trial. The study is evaluating a new, consolidated dosing schedule for intravenous BRIUMVI® (ublituximab-xiiy) in individuals with relapsing forms of multiple sclerosis (RMS). The trial is designed to assess whether combining the Day 1 and Day 15 infusions into a single Day 1 infusion maintains drug exposure levels comparable to the existing approved regimen. The primary endpoint is non-inferior exposure with respect to area under the curve (AUC) at week 16. Results from the study have not yet been presented, and if positive, TG Therapeutics anticipates that the new dosing regimen could be available for launch in 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9563178-en) on October 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.